{
  "id": 9278586,
  "title": "Roche’s sefaxersen shows positive results in kidney disease trial",
  "url": "https://urgent.news/2026/09/23/roches-sefaxersen-shows-positive-results-in-kidney-disease-trial",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-23T05:26:13.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/stock-market-news/roches-sefaxersen-shows-positive-results-in-kidney-disease-trial-93CH-4912083"
  },
  "original_language": "en",
  "account": "Roche Holding AG announced that its drug sefaxersen demonstrated positive results in a phase III trial for IgA nephropathy, a kidney disease. The IMAGINATION study, which met its primary endpoint at 37 weeks, showed sefaxersen's potential to be best-in-class in reducing proteinuria compared to placebo. Proteinuria, excess protein in urine, is a critical marker for this condition. Sefaxersen's safety and tolerability profile remained consistent with prior data, and no new safety concerns emerged during the trial. Roche plans to present interim data at an upcoming medical conference and will share results with regulatory authorities, though no submission timeline was specified.",
  "summary": null,
  "key_points": [
    "Sefaxersen showed positive results in phase III trial for IgA nephropathy.",
    "IMAGINATION study met primary endpoint at 37 weeks, reducing proteinuria.",
    "Safety profile consistent with prior data, no new safety concerns."
  ],
  "editors_take": "The positive trial results position sefaxersen as a potential top treatment option for IgA nephropathy, a kidney disease, by showing it can reduce a critical marker of the condition better than placebo.",
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}